¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦10ȸ »ï¼º¾È°ú ½ÉÆ÷Áö¾ö(³ì³»Àå) : 2023-07-08

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Á¦10ȸ »ï¼º¾È°ú ½ÉÆ÷Áö¾ö(³ì³»Àå) : 2023-07-08
±³À°ÀÏÀÚ : 2023-07-08
±³À°Àå¼Ò : »ï¼º¼­¿ïº´¿ø ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç

±³À°ÁÖÁ¦ : Á¦10ȸ »ï¼º¾È°ú ½ÉÆ÷Áö¾ö(³ì³»Àå)

ÁÖÃÖ±â°ü : »ï¼º¼­¿ïº´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¾È°ú

´ã´çÀÚ : ¹Ú¹Ì³ª
¿¬¶ôó : 02-3410-3569

À̸ÞÀÏ : minasun.park@samsung.com

±³À°Á¾·ù : ÀÇ»çÇÐ

Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 25ºÐ

¼¼ºÎ¼ö°­·á : 0¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 08:55~09:00 °³È¸»ç ÇÔµ·ÀÏ(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 09:00~09:10 Anatomy in glaucoma ÀÌÀºÁ¤(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 09:10~09:20 Molecular biology in glaucoma Á¶Çö°æ(°æ»óÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 09:20~09:30 Pathophysiology in glaucoma ±è¿µ±¹(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 09:30~09:40 Animal models in glaucoma ³ë½Â¼ö(Â÷ÀÇ°úÇдë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 09:40~09:50 Lymphatics and glaucoma ¹Úµµ¿µ(¼º±Õ°üÀÇ´ë)

Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 09:50~10:10 Discussion ( )

ÈÞ½Ä 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 10:10~10:25 Coffee Break ( )

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 10:25~10:35 Myopia: How does it affect glaucoma? ±è¸¶¸£´Ù(µ¿±¹ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 10:35~10:45 Optic disc morphology: Does It predict the future VF defect pattern? ÇÑÁ¾Ã¶(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 10:45~10:55 FDT & 10-2 VF: Do they offer additional information? Á¤°æÀÎ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 10:55~11:05 AngioOCT: The tips how to use AngioOCT in glaucoma clinic ¼­¹ÎÈñ(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 11:05~11:15 ICP: The influence of CSF pressure in glaucoma ±è°íÀº(¿ï»êÀÇ´ë)

Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 11:15~11:35 Discussion ( )

±âŸ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 11:35~12:05 Special Session :³ì³»Àå°ú ÇÔ²²ÇÑ 30¿©³â ±ââ¿ø(¼º±Õ°üÀÇ´ë)

½Ä»ç 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ǪµåÄÚÆ® 12:05~13:30 LUNCH ( )

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 13:30~13:40 Congenital glaucoma ¼­¿ï(ÀÌÈ­ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 13:40~13:50 Traumatic glaucoma ÀÌ°æ¹Î(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 13:50~14:00 Uveitic glaucoma ÃÖÁø¾Æ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 14:00~14:10 Pseudoexfoliative glaucoma ±èÁ¤¸²(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 14:10~14:20 Neovascular glaucoma ÀÌÁö¿õ(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 14:20~14:30 Malignant glaucoma ÀÌÅÂÀº(ÀüºÏÀÇ´ë)

Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 14:30~14:50 Discussion ( )

ÈÞ½Ä 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 14:50~15:05 Coffee Break ( )

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 15:05~15:20 How to interpret the measured IOP in clinic when we consider the diurnal variation of IOP À¯Á¤±Ç(°í·ÁÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 15:20~15:35 How to determine the progression when we meet glaucoma patients with VF progression but without ONH change. ¹èÇü¿ø(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 15:35~15:50 Targeting IOP: What should we do when we meet persistent progression of glaucoma patients with low teen IOP? ÀÌÀºÁö(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 15:50~16:05 Why are there many NTG patients in Asian population? Á¤Áø¿í(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 16:05~16:20 Strategies for neuroprotection: Which should be the main target – ganglion cell, axon, or glial cell? ¹ÚÇý¿µ(°¡Å縯ÀÇ´ë)

Åä·Ð 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 16:20~16:50 Discussion ( )

±âŸ 07¿ù 08ÀÏ ¾Ïº´¿ø ÁöÇÏ1Ãþ ´ë°­´ç 16:50~16:55 Æóȸ»ç ( )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦10ȸ »ï¼º¾È°ú ½ÉÆ÷Áö¾ö(³ì³»Àå) : 2023-07-08""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023 ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2023-07-09
´ÙÀ½±Û APCCMI 2023 & ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸ Á¦26Â÷ Çмú´ëȸ (3ÀÏÂ÷) : 2023-07-08
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20910 ¼­¿ï 2024³â Á¦14ȸ °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ³»°ú ¿¬¼ö°­Á : 2024-07-07 0 2 2024-05-28
20909 °æ±â ¾ÆÁÖ´ëÇб³º´¿ø Á¤Çü¿Ü°ú 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-07-07 0 2 2024-05-28
20908 ¼­¿ï Á¦19Â÷ ´ëÇѸðÀ¯¼öÀ¯ÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-07-07 0 2 2024-05-28
20907 °æ±â Á¦2Â÷ ´ëÇѽŰæ¹æ»ç¼±¼ö¼úÇÐȸ Á¤±âÇмú´ëȸ : 2024-07-06 0 2 2024-05-28
20906 °æ±â Á¦ 5ȸ ¿À»ê½ÃÀÇ»çȸ Çмú´ëȸ : 2024-07-06 0 1 2024-05-28
20905 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Á¦3ȸ ¾Æ»êµÎ°æºÎ Æ÷·³ : 2024-07-06 0 1 2024-05-28
20904 ¼­¿ï 2024³â Á¦2ȸ °¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø ¼øȯ±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-06 0 6 2024-05-28
20903 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day3) : 2024-07-06 0 2 2024-05-28
20902 ¼­¿ï ´ëÇѽŰæÁýÁßÄ¡·áÇÐȸ 2024³â ÇÏ°è NeurocrItical Care Essence (NICE) ¾ÆÄ«µ¥¹Ì : 2024-07-06 0 1 2024-05-28
20901 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø Á¦10ȸ ºÎ½Å¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06 0 1 2024-05-28
20900 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day2) : 2024-07-05 0 1 2024-05-28
20899 ¼­¿ï ÀÓ»ó¼ú±â±³À°¿¬±¸È¸ Á¦16ȸ ÀÓ»ó¼ú±â ¿¬¼ö°­Á : 2024-07-04 0 1 2024-05-28
20898 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 1 2024-05-28
20897 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 0 2024-05-28
20896 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 0 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷